Filing Flows › ANI Pharmaceuticals (ANIP) › R&D spending
ANI Pharmaceuticals (ANIP) R&D spending by quarter
ANI Pharmaceuticals' R&D spending was $13.0M in Q3 2026 (third quarter 2026), -12% from Q2 2026. Over the last 7 quarters it ranged from $10.6M (Q1 2025) to $16.5M (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $13.0M | -12% | +6% |
| Q2 2026 | $14.7M | +39% | -11% |
| Q1 2026 | $10.6M | -14% | +0.3% |
| Q4 2025 | $12.3M | -0.3% | — |
| Q3 2025 | $12.3M | -26% | — |
| Q2 2025 | $16.5M | +57% | — |
| Q1 2025 | $10.6M | — | — |
Q3 2026 at a glance
ANI Pharmaceuticals, Q3 2026: revenue $291M (+28% year over year), operating margin 18.0%, net earnings $35.1M, operating cash flow $83.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is ANI Pharmaceuticals' R&D spending?
ANI Pharmaceuticals' R&D spending was $13.0M in Q3 2026 (third quarter 2026), -12% from Q2 2026.
How has ANI Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $10.6M (Q1 2025) to $16.5M (Q2 2025).